Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award on 11/28/2025. The filing shows an award of 10,314 shares of common stock, recorded at a price of $0 as a grant of deferred stock units to a non-employee member of the Board of Directors. Following this grant, the director beneficially owns 88,714 shares of Elanco common stock in direct ownership. This is a routine Form 4 disclosure of director compensation in equity rather than a cash transaction.
Elanco Animal Health Inc. reported an equity award to one of its directors. On 11/28/2025, director Kirk P. McDonald received a grant of 10,314 shares of common stock in the form of deferred stock units as an annual equity award for non-employee board members, at a stated price of $0 per share.
Following this award, McDonald beneficially owns 88,714 shares of Elanco common stock in direct ownership. The filing reflects standard board compensation and does not describe any cash transaction for the company.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the reporting person acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open‑market purchase. Following this award, the director beneficially owned 121,773 shares of Elanco common stock in direct ownership. The grant is described as an annual equity award to each non‑employee member of the company’s board of directors.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open-market purchase. Following this transaction, the director beneficially owns 89,714 shares of Elanco common stock held directly.
The filing notes that this award is part of the regular annual equity compensation provided to non‑employee members of Elanco’s Board of Directors, aligning director pay with shareholder interests through stock-based compensation.
Elanco Animal Health Inc. director R. David Hoover reported an equity grant tied to his board service. On 11/28/2025, he received 10,314 shares of common stock as an annual equity award in the form of deferred stock units at a stated price of $0, reflecting a non-cash grant for a non-employee director. After this grant, he beneficially owns 106,773 shares of Elanco common stock directly and an additional 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust. The filing is made as a Form 4 by a single reporting person in his capacity as a director.
Elanco Animal Health Inc. reported that a board director received an annual equity grant in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock-equivalent deferred units at a stated price of $0 as an equity award for non-employee members of the Board of Directors. Following this grant, the director beneficially owns 84,813 shares of Elanco common stock in direct form. These awards align the director’s compensation more closely with long-term shareholder value through stock-based incentives.
Elanco Animal Health director reports equity grant
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a reported price of $0, reflecting that this was an equity grant rather than an open‑market purchase. Following this transaction, the director beneficially owned 91,278 shares of Elanco common stock in direct ownership. The award is described as part of the regular annual equity compensation for non‑employee members of the company’s Board of Directors.
Elanco Animal Health Inc. (ELAN) reported an insider equity award for a member of its Board of Directors. On 11/28/2025, director Michael J. Harrington received 10,314 shares of common stock, recorded at a price of $0 per share, reflecting a grant rather than a market purchase. Following this transaction, he beneficially owned 109,577 shares of Elanco common stock in direct ownership. The company explains that this grant represents deferred stock units issued as an annual equity award to each non-employee member of the Board of Directors, aligning director compensation with shareholder interests through stock-based incentives.
Elanco Animal Health Inc. (ELAN) reported a Form 4 filing for executive officer Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation. On 11/14/2025, he acquired 67.0754 deferred stock units at a price of $21.09 per unit. Following this transaction, he beneficially owns 7,230.2452 deferred stock units, held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these deferred stock units will settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health Inc. executive Jeffrey N. Simmons, the company’s President, CEO and Director, reported a new equity-related award. On 11/14/2025, he acquired 131.3058 deferred stock units at a reference price of $21.09 per unit. After this transaction, he beneficially owned 18,355.9214 derivative securities, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units are designed to settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.